Is Klebsiella a rare pathogen causing central‑line associated bloodstream infections (CLABSI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Klebsiella a Rare Pathogen in Central Line Infections?

No, Klebsiella is not a rare pathogen in central line-associated bloodstream infections (CLABSI), though it is less common than Gram-positive organisms. Klebsiella species account for approximately 3-5% of hospital-acquired bloodstream infections and are part of the expected spectrum of Gram-negative pathogens causing CLABSI 1.

Epidemiologic Context

Gram-negative bacteria, including Klebsiella, represent 20-25% of all catheter-related bloodstream infections, making them a substantial minority of CLABSI cases 1, 2. Within the Gram-negative category specifically:

  • Klebsiella pneumoniae accounted for 4% of hospital-acquired BSIs during 1986-1989 and 3% during 1992-1999 in CDC surveillance data 1
  • In oncology and hematology patients, Gram-negative bacteria (including E. coli, Pseudomonas aeruginosa, and Klebsiella spp.) collectively cause 20-25% of CRBSI 1
  • The predominant pathogens remain Gram-positive cocci (60-70% of cases), with coagulase-negative staphylococci being most common at 37% 1

Clinical Significance Despite Lower Frequency

While numerically less common than staphylococcal infections, Klebsiella CLABSI carries important clinical implications:

  • Antimicrobial resistance is a major concern, with increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing strains that resist broad-spectrum cephalosporins and other commonly used agents 1
  • Multidrug-resistant Klebsiella pneumoniae has been identified as a predominant cause of CLABSI in some institutional studies, particularly in ICU settings 3
  • Carbapenem-resistant Klebsiella pneumoniae has emerged as a cause of healthcare-associated infections, including CLABSI 4

Risk Stratification for Gram-Negative Coverage

Empiric coverage for Gram-negative organisms including Klebsiella should be considered in specific high-risk scenarios 1:

  • Severe illness, hemodynamic instability, or septic shock
  • Neutropenic or immunocompromised patients
  • Femoral catheter placement
  • Prolonged catheterization (>1 week)
  • ICU patients, where Klebsiella resistance rates are higher 5

Treatment Implications

When Klebsiella is isolated from blood cultures in the setting of a central line:

  • Catheter removal is generally recommended for Gram-negative CRBSI 6, 7
  • Treatment duration is typically 10-14 days of IV antibiotics after catheter removal 6
  • Antibiotic selection must account for local resistance patterns, particularly ESBL production 1

Common Pitfall to Avoid

Do not dismiss Klebsiella as "just a contaminant" when isolated from central line blood cultures. Unlike coagulase-negative staphylococci (which may represent contamination), Gram-negative organisms including Klebsiella are rarely skin contaminants and typically represent true infection requiring catheter removal and appropriate antimicrobial therapy 1, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Central Lines and Gram-Negative Bacilli Bacteremia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Catheter-Related Bloodstream Infections (CRBSI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Central Line-Associated Bloodstream Infections (CLABSI) and Catheter-Related Bloodstream Infections (CRBSI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.